RABELLE SIDDIKI: Open Payments
NPI 1912764846 · RESTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,135 in 214 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $1,992 · 2025 $5,135
Food & beverage: $5,135
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 65 | $1,202 |
| Gilead Sciences, Inc. | 16 | $555 |
| PFIZER INC. | 28 | $450 |
| Madrigal Pharmaceuticals | 11 | $441 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $421 |
| Janssen Biotech, Inc. | 11 | $385 |
| QOL Medical, LLC | 13 | $353 |
| GENZYME CORPORATION | 9 | $227 |
| Lilly USA, LLC | 7 | $209 |
| Regeneron Healthcare Solutions, Inc. | 6 | $177 |
Products named: RINVOQ, REZDIFFRA, SKYRIZI, TREMFYA, ENTYVIO, Sucraid, DUPIXENT, Livdelzi.
Industry payments across VA — which companies pay providers there.
